Literature DB >> 9164544

Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer.

C T Shun1, M S Wu, J T Lin, S Y Chen, H P Wang, W J Lee, T H Wang, S M Chuang.   

Abstract

BACKGROUND/AIMS: Conflicting results concerning the relationships between abnormal expression of p53 and c-erbB-2 and biologic behavior of gastric cancer are noted. Therefore, overexpression of p53 and c-erbB-2 in relation to the following aspects of gastric cancer: tumor histopathology, Helicobacter pylori infection, and prognosis are explored.
MATERIALS AND METHODS: Expression of p53 and c-erbB-2 by immunohistochemistry was correlated with histopathology, H. pylori infection and prognosis of gastric cancer in 112 patients.
RESULTS: Positive p53 staining was found in 61 (54.5%) of 112 tumors examined. There was no association of p53 expression with sex, age, lymph node metastasis, H. pylori infection or prognosis. A significantly higher frequency of p53-positive staining was observed in advanced (60.7%), intestinal (69.8%) and cardia (76.5%) than in early (30.4%, p < 0.01), diffuse (34.7%, p < 0.01) and noncardia (50.5%, p < 0.05) carcinoma, respectively. Expression of c-erbB-2 was found in 34 cases (30.3%), and was not related to sex, age, H. pylori infection and tumor location. Tumors with positive c-erbB-2 staining appeared to behave more aggressively in view of higher rates of nodal metastasis (38.0% vs 17.1%, p < 0.05), advanced stage (37.1% vs 4.3%, p < 0.01) and poor mean survival (p < 0.01). Patients with intestinal type tumors also had a significantly higher rate of c-erbB-2 expression than those with diffuse tumors (39.7% vs 18.4%, p < 0.01).
CONCLUSIONS: Our results indicate that immunohistochemical expressions of p53 and c-erbB-2 are significantly associated with some histopathological phenotypes. Genetic alterations of c-erbB-2 or p53 may not be affected by H. pylori infection. C-erbB-2 expression may be used as a marker for identifying more aggressive gastric cancer for designing further therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9164544

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  16 in total

1.  Infrequent p53 gene mutation and expression of the cardia adenocarcinomas from a high-incidence area of Southwest China.

Authors:  Xiu-Jie Wang; Shu-Lan Yuan; Chang-Ping Li; Naoko Iida; Hideaki Oda; Shigetoshi Aiso; Takatoshi Ishikawa
Journal:  World J Gastroenterol       Date:  2000-10       Impact factor: 5.742

2.  Multiple genetic alterations and behavior of cellular biology in gastric cancer and other gastric mucosal lesions:H.pylori infection, histological types and staging.

Authors:  Heng-Jun Gao; Lian-Zhen Yu; Jian-Feng Bai; Yan-Shen Peng; Gu Sun; Han-Lin Zhao; Kun Miu; Xiu-Zhen L ; Xiao-Yong Zhang; Zhi-Quan Zhao
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

3.  p53 abnormalities in adenocarcinoma of the gastric cardia and antrum.

Authors:  J F Fléjou; V Gratio; F Muzeau; R Hamelin
Journal:  Mol Pathol       Date:  1999-10

4.  Prognostic significance of immunohistochemical expression of EGFR and C-erbB-2 oncoprotein in curatively resected gastric cancer.

Authors:  Hong Suk Song; Young Rok Do; In Ho Kim; Soo Sang Sohn; Kun Young Kwon
Journal:  Cancer Res Treat       Date:  2004-08-31       Impact factor: 4.679

5.  TGF-β Regulates Survivin to Affect Cell Cycle and the Expression of EGFR and MMP9 in Glioblastoma.

Authors:  Wenliang Chen; Xiao Zhong; Yi Wei; Yun Liu; Quan Yi; Genshui Zhang; Lishan He; Fajiang Chen; Yingping Liu; Jiandong Luo
Journal:  Mol Neurobiol       Date:  2015-02-17       Impact factor: 5.590

6.  Use of protein array technology to investigate receptor tyrosine kinases activated in hepatocellular carcinoma.

Authors:  Shi Liu; Jian Gong; Asahiro Morishita; Takako Nomura; Hisaaki Miyoshi; Joji Tani; Kiyohito Kato; Hirohito Yoneyama; Akihiro Deguchi; Hirohito Mori; Shima Mimura; Kei Nomura; Takashi Himoto; Kazushi Deguchi; Keiichi Okano; Kunihiko Izuishi; Yasuyuki Suzuki; Yoshio Kushida; Reiji Haba; Hisakazu Iwama; Tsutomu Masaki
Journal:  Exp Ther Med       Date:  2011-02-08       Impact factor: 2.447

7.  MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.

Authors:  Jochen K Lennerz; Eunice L Kwak; Allison Ackerman; Michael Michael; Stephen B Fox; Kristin Bergethon; Gregory Y Lauwers; James G Christensen; Keith D Wilner; Daniel A Haber; Ravi Salgia; Yung-Jue Bang; Jeffrey W Clark; Benjamin J Solomon; A John Iafrate
Journal:  J Clin Oncol       Date:  2011-10-31       Impact factor: 44.544

8.  A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma, based on correlation of fluorescence in situ hybridization and immunohistochemical measurements.

Authors:  Mikihiko Kimura; Hitoshi Tsuda; Daisaku Morita; Takashi Ichikura; Sho Ogata; Shinsuke Aida; Yutaka Yoshizumi; Tadaaki Maehara; Hidetaka Mochizuki; Osamu Matsubara
Journal:  Virchows Arch       Date:  2004-07-28       Impact factor: 4.064

9.  p53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer: relation to histological subtypes, Helicobacter pylori infection, and prognosis.

Authors:  Stefan Kubicka; Christiane Claas; Sven Staab; Florian Kühnel; Lars Zender; Christian Trautwein; Siegfried Wagner; Karl Lenhard Rudolph; Michael Manns
Journal:  Dig Dis Sci       Date:  2002-01       Impact factor: 3.199

Review 10.  CXC chemokines and chemokine receptors in gastric cancer: from basic findings towards therapeutic targeting.

Authors:  Hyo Jin Lee; Ik-Chan Song; Hwan-Jung Yun; Deog-Yeon Jo; Samyong Kim
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.